LEVERAGE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 10:00:00 24/05/2024 pm IST | ||
| 26.67 EUR | -9.87% |
|
| Current month | +15.58% | ||
| 1 month | +30.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 26.19 | -11.49% |
| 23/24/23 | 29.59 | +20.78% |
| 22/24/22 | 24.5 | -1.05% |
| 21/24/21 | 24.76 | +12.75% |
| 20/24/20 | 21.96 | +7.81% |
Real-time Euronext Paris
Last update May 24, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| SU58S | |
| ISIN | DE000SQ70QS4 |
| Date issued | 17/01/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 5.09 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 57.45 € |
|---|---|
| Lowest since issue | 1.982 € |
| Spread | 1.87 € |
| Spread % | 6.77% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
928.8
DKK
Average target price
909.2
DKK
Spread / Average Target
-2.11%
- Stock Market
- Certificates
- SU58S Certificat
